A UK firm has developed a test that can detect Coronavirus within 10 minutes and render both self-isolation and incubation unnecessary.

The test developed by SureScreen Diagnostics in Derby checks a patient’s blood in a simple procedure and shows up Coronavirus between three to seven days after infection – before symptoms begin to appear.

The test, which has an accuracy of 98.7% has been validated in China and is already being used in the UK, Ireland, Germany, Spain, Switzerland, Netherlands, Turkey, UAE, Kuwait and Oman.

SureScreen can produce up to 500,000 of the tests every week and believe they could have discovered a game-changer when it comes to the handling of the Coronavirus crisis.

Director David Campbell said: “We’ve been working hard to produce a coronavirus test (COVID19) that can be used at the patient side, with capillary blood, easily taken from someone’s fingertip and diagnose them within 10 minutes.

“There is a big problem with the diagnosis of the disease currently because the standard method of screening is to send samples to the laboratory, which takes a lot of time.  Meanwhile, someone could be spreading the virus without knowing, or having the issue of self-isolation.

“I’ve only seen one other similar test which is made in China and only tests for one biomarker, whereas ours screens for two which increases the accuracy greatly (which can be seen in the clinical data.)

“Most test kits are a swab, which is used to sample sputum (oral mucous), which then gets sent back to the laboratory.  This takes time and cost, and, meanwhile, the individual has to self-isolate.

“Our key differentiator is the speed and ease of use at the patient side without the need for big equipment or unnecessary isolation.

“Plus it’s a fraction of the cost against lab screening.

“It’s a product that is ready to go with clinical data behind it and already compared against real-world samples.

Approximately, 175,000 tests have been conducted with the SureScreen kit so far with potential orders for over two million over the next month.

Private companies are now moving to test their staff and one multinational oil and gas firm and a cruise liner firm have ordered supplies.

David added: ” It’s particularly powerful for businesses where they have a lot of international travel, as the disruption self-isolation, or spreading the infection can cause can have a bit impact on the business.  We believe the test could be used in GPs, hospitals, airports, pharmacies,  incubation centres, border controls, Occupational Health and in general screening programmes.

This was an article by Medilink EM Member, Surescreen Diagnostics.

For more information on Medilink EM membership, click here

To read the associated SureScreen Diagnostics Whitepaper, click here

Latest Opportunities

Single manufacturer & supplier required for human skin patch: Formulation, manufacture, and packing

Opportunity Company:  Nottingham-based MedTech company Requires: Seeking a single manufacturer and supplier for the formulation,…

Medilink Midlands Job Vacancy - Innovation Adviser

About the job Innovation Adviser – Midlands region – Full time salary £40-45K – Home…

Global Business Innovation Programme: Health & Medical Technologies - Singapore

Innovate UK is inviting ambitious innovative companies to participate in its Global Business Innovation Programme…

Latest News

Cambridge Sleep Sciences Unveils World-First Performance Pillow That Adapts to Users’ Sleep

Cambridge Sleep Sciences Unveils World-First Performance Pillow That Adapts to Users’ Sleep – Helping Gamers…

Kindeva Opens New UK HQ and Manufacturing Site for the Development of Next-Generation Propellants

Kindeva, a global CDMO and drug delivery expert, has officially opened its new UK headquarters…

EU MDR/IVDR Revision: A Gateway for Chinese Innovators Entering UK and EU Markets via EFEC

In a significant move for the global medtech landscape, the European Commission has initiated a…